BISPECIFIC OR-GATE CHIMERIC ANTIGEN RECEPTOR RESPONSIVE TO CD20 and CD19
AssigneesThe Regents of the University of California, Seattle Children's Hospital (dba Seattle Children's Research Institute)
InventorsYvonne Y. Chen, Eugenia Zah, Michael C. Jensen
Life of this patent
Estimating the term…
Abstract
A CD19-OR-CD20 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD19-OR-CD20 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD19-OR-CD20 CAR of the invention is a bispecific CAR that can trigger T-cell activation upon detection of either CD19 or CD20 (or both). It is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR.
Claims22
1-16. (canceled)
A method of assessing at least one property in a population of T cells expressing a polypeptide comprising a CD19-OR-CD20 chimeric antigen receptor (CAR), the CAR comprising, in order:
- anti-CD20 scFv comprising a light chain variable region and heavy chain variable region from SEQ ID NO:3;
- (G4S)4 linker;
- anti-CD19 scFv comprising a heavy chain variable region and light chain variable region from SEQ ID NO:4;
- spacer domain of SEQ ID NO:5;
- transmembrane domain of SEQ ID NO:6;
- 4-1BB cytoplasmic signaling domain of SEQ ID NO:8;
- and CD3 zeta cytoplasmic signaling domain of SEQ ID NO:9;
- and
- wherein the at least one property is selected from the group consisting of surface expression of at least one activation-induced marker on the T cells, cell lysis of target cells, release of at least one cytokine in the presence of target cells, bispecificity of the CAR, and abrogation of the effects of antigen escape.
A method of assessing at least one property in a population of T cells expressing a polypeptide comprising a CD19-OR-CD20 chimeric antigen receptor (CAR), wherein the CAR comprises from N- to C-terminus:
- a) an anti-CD20 scFv consisting of a variable light domain and a variable heavy domain from ofatumumab;
- b) a (G4S)n linker, wherein n is 1 (SEQ ID NO:
- 15), 3 (SEQ ID NO:
- 16), or 4 (SEQ ID NO:
- 19);
- c) an anti-CD19 scFv comprising a variable heavy domain and a variable light domain from a sequence of SEQ ID NO:
- 4;
- d) a spacer of SEQ ID NO:
- 5;
- e) a transmembrane domain of SEQ ID NO:
- 6;
- f) a co-stimulatory domain of SEQ ID NO:
- 8;
- and
- g) a CD3-zeta cytoplasmic signaling domain of SEQ ID NO:
- 9,
- wherein the at least one property is selected from the group consisting of surface expression of at least one activation-induced marker on the T cells, cell lysis of target cells, release of at least one cytokine in the presence of target cells, bispecificity of the CAR, and abrogation of the effects of antigen escape.
A method of assessing at least one property in a population of T cells expressing a polypeptide comprising a CD19-OR-CD20 chimeric antigen receptor (CAR), wherein the CAR comprises from N-to C-terminus:
- a) an anti-CD20 scFv comprising a variable heavy domain and a variable light domain from a sequence of SEQ ID NO:
- 3;
- b) a flexible peptide linker consisting of Gly and Ser residues;
- c) an anti-CD19 scFv comprising a variable light domain and a variable heavy domain from a sequence of SEQ ID NO:
- 4;
- d) a spacer domain;
- e) a transmembrane domain;
- f) a co-stimulatory domain of SEQ ID NO:
- 8;
- and
- g) a CD3-zeta cytoplasmic signaling domain of SEQ ID NO:
- 9,
- wherein the at least one property is selected from the group consisting of surface expression of at least one activation-induced marker on the T cells, cell lysis of target cells, release of at least one cytokine in the presence of target cells, bispecificity of the CAR, and abrogation of the effects of antigen escape.
Dependencies are inferred from the claim text.